Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1318-1332

  Swain, S M ^a   Whaley, F S ^a   Gerber, M C ^a   Weisberg, S ^a   York, M ^a   Spicer, D ^a   Jones, S E ^a   Wadler, S ^a   Desai, A ^a   Vogel, C ^a   Speyer, J ^a   Mittelman, A ^a   Reddy, S ^a   Pendergrass, K ^a   Velez Garcia, E ^a   Ewer, M S ^a   Bianchine, J R ^a   Gams, R A ^a  

^a Comprehensive Breast Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LACTOSE; MANNITOL; PLACEBO; RAZOXANE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FEVER; FEMALE; GRANULOCYTOPENIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 0030904096     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1318     Document Type: Article

References (39)

1. Tormey DC: Adriamycin (NSC-123127) in breast cancer: An overview of studies. Cancer Chemother Rep 6:319-327, 1975
2. Henderson CI: Chemotherapy for metastatic disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases (ed 2). Philadelphia, PA, Lippincott, 1991, pp 604-664
3. Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317:1490-1495, 1987
4. Minow RA, Benjamin RS, Gottlieb JA: Adriamycin (NSC-123127) cardiomyopathy - An overview with determination of risk factors, part 3. Cancer Chemother Rep 6:195-201, 1975
5. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-711, 1979
6. Billingham ME, Bristow MR, Glabstein E, et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17-23, 1977
7. Dresdale A, Bonow O, Wesley R, et al: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51-60, 1983
8. Bristow MR, Thompson PD, Martin RP, et al: Early anthracy-cline cardiotoxicity. Am J Med 65:823-832, 1978
9. Schwartz RG, McKenzie WB, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy - Seven-year experience using serial radionuclide angio-cardiography. Am J Med 82:1109-1118, 1987
10. Speyer JL, Green MD, Dubin N, et al: Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 78:555-563, 1985
11. Marshall RC, Berger H, Reduto LA, et al: Variability in sequential measures of left ventricular performance assessed with radionuclide angiocardiography. Am J Cardiol 41:531-536, 1978
12. Weiss AJ, Metter CE, Fletcher WS, et al: Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813-822, 1976
13. Torti MF, Bristow MR, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 99:745-749, 1983
14. Legha SS, Benjamin RS, Mackey B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
15. Jain KK, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
16. Sells RA, Gilmore IT, Owen RR, et al: Reduction in doxorubicin toxicity following liposomal delivery. Cancer Treat Rev 14:383-387, 1987
17. Myers CE, McGuire WP, Liss RH, et al: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167, 1977
18. Creighton AM, Hellmann K, Whitecross S: Antitumor activity in a series of bisdiketopiperazines. Nature 222:384-385, 1969
19. Herman EH, Mhatre RM, Lee IP, et al: Prevention of the cardiotoxic effects of Adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med 140:234-239, 1972
20. Herman EH, Mhatre RM, Chadwick DP: Modification of some of the toxic effects of daunomycin (NSC-82, 151) by pretreatment with the antineoplastic agent ICRF-159 (NSC-129,943). Toxicol Appl Pharmacol 27:517-526, 1974
21. Herman EH, Ferrans VJ, Jordan W, et al: Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31:85-97, 1981
22. Verhoef V: Effect of ADR-529 (ICRF-187) on the antitumor activity of doxorubicin in mouse models of murine and human cancer. Dublin, OH, Adria Labs Internal Report no. PLS 87-08, 203i. April 13, 1987, p 73
23. Green MD, Speyer JL, Stecy P, et al: ICRF-187 (ICRF) prevents doxorubicin (DOX) cardiotoxicity (CTOX): Results of a randomized clinical trial. Proc Am Soc Clin Oncol 6:28, 1987 (abstr)
24. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
25. Swain SM, Whaley FS, Gerber MC, et al: Delayed Administration of Dexrazoxane Provides Cardioprotection for Patients with Advanced Breast Cancer Treated with Doxorubicin-containing Therapy. J Clin Oncol 15:1333-1340, 1997
26. Speyer JL, Green MD, Kramer E, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988
27. Speyer JL, Green MD, Zeleniuck-Jacqiotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
28. Colborn D, Verhoef V: Effect of ADR-529 on the antitumor activity of 5 fluorouracil, cyclophosphamide and epirubicin against murine leukemias and solid tumors. Dublin, OH, Adria Labs Internal Report no. PLS 89-08; April 7, 1980, p 29
29. Pastori A, Sola F, Grandi M: Effect of ADR-529 on the antitumoral activity of doxorubicin against advanced mx-1 human mammary carcinoma implanted subcutaneously in immunodeficient athymic nude mice. Dublin, OH, Pharmacia Internal Report no. 243. October 1993
30. Wadler S, Green MD, Basch R, et al: Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2, -bis (3-5-dioxopiperazinyl)-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitro. Biochem Pharmacol 36:1495-1501, 1987
31. Speyer JL, Green MD, Sanger J, et al: A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 17:161-163, 1990
32. Michelotti A, Venturini M, Conte PF, et al: Cardioxane (ICRF-187) protects against epirubicin (EPI) induced cardiomyopathy in advanced breast cancer (ABC) patients. A phase III study. Proc Am Soc Clin Oncol 14:98, 1995 (abstr)
33. Zalupski M, Metch B, Balcerzak S, et al: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study. J Natl Cancer Inst 83:926-932, 1991
34. Forssen EA, Tokes ZA: Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA 78:1873-1877, 1981
35. Rahman A, Kessler A, More N, et al: Liposomal protection of Adriamycin-induced cardiotoxicity in mice. Cancer Res 40:1532-1537, 1980
36. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1985
37. Singal PK, Siveski-Iliskovic N, Hill M, et al: Combination therapy with probucol prevents Adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 27:1055-1063, 1995
38. Muss HB, Case LD, Richards F II, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325:1342-1348, 1991
39. Harris AL, Cantwell BMJ, Carmichael J, et al: Comparison of short-term and continuous chemotherapy (mitoxantrone) for advanced breast cancer. Lancet 335:186-190, 1990